Xconomy

JULY 7, 2016

As of the end of 2015, Pernix reported a headcount of 274. Consequently, Pernix’s stock price has suffered. Last month, Pernix disclosed that it risked delisting from the Nasdaq because its stock price had fallen below $1. But filings also show the company’s net losses widening each year since 2012. million net loss.

Sales 40

Sales San Diego .Net Report 40

Tech Zulu Event

APRIL 18, 2016

Many retailers report $100,000 is the minimum price of entry. The price of a retail app varies depending on the developer and features; nevertheless, it’s a big number. RetailNext data shows that sales over the 2015 Thanksgiving weekend were down by 4.7 percent in brick and mortar stores. MYTH: Consumers won’t download the app.

Mobile 40

Mobile Sites Customer Custom 40

Xconomy

AUGUST 26, 2016

According to a 2015 report from EvaluatePharma , the market for drugs for rare, or “orphan” diseases, as they’re known, has been growing by 12 percent every year and is expected to reach $178 billion worldwide by 2020. Twenty-one orphan drugs were approved in 2015, a record for the second straight year.

Research 40

Research Organization Help Report 40

Xconomy

JUNE 3, 2016

AstraZeneca got the drug when it bought ZS Pharma in late 2015 for $2.7 A company official told Xconomy the drug would be priced in line with standard of care enzyme replacement therapy, which costs around $300,000 per patient, per year. The drug has a list price of $69,350 per patient, per year.

San Diego 62

San Diego Patents Acquisition News 62

Xconomy

OCTOBER 14, 2016

in July 2015. The stock price was down 10 percent as of Thursday’s close. . —Shares of San Diego-based Illumina (NASDAQ: ILMN ) fell more than 32 percent after the next-gen sequencing giant slashed its revenue projections once again. But sagging sales have sent Illumina far down from last year’s peak. Here’s more from CNBC.

News 40

News San Diego Incubator Research 40

Xconomy

JULY 21, 2016

After a year in which Biogen’s share price has fallen by more than a third and one of its top drug prospects failed, Scangos, who has led the company since 2010, has announced plans to step down. In January 2015, Biogen shares were at over $400 apiece as the company was gaining steam on early positive signals for aducanumab.

San Diego 40

San Diego Conference Pricing Acquisition 40

Xconomy

SEPTEMBER 2, 2016

The firm raised $450 million in January 2015. The companies—Amgen, Sanofi, and Regeneron Pharmaceuticals—are due to release important long-term data next year that will shape the debate over the drugs’ prices. The firm has nabbed $451 million toward its goal of $600 million. He was a professor at UC San Diego.

News 57

News San Diego Journal Technical Review 57

Xconomy

AUGUST 12, 2016

The news was a relief for Redwood City, CA-based Heron, which has been waiting for word on the status of its drug since September 2015. . —Heron Therapeutics (NASDAQ: HRTX ) won FDA approval of granisetron (Sustol) , a drug it developed for the nausea and vomiting associated with certain chemotherapy regimens. In the U.S.,

Google 40

Google Technical Review News Research 40

Xconomy

NOVEMBER 4, 2016

Its owner Pfizer (NYSE: PFE ) shelved it this week , citing poor Phase 3 data and pricing pressures on the two approved PCSK9 drugs. Photo of Tony Coles and Sue Lindquist at Xconomy’s “What’s Hot In Boston Biotech” event, April 2015. One latecomer, bococizumab, won’t even reach approval.

Research 40

Research Report Pricing Journal 40

Both Sides of the Table

FEBRUARY 14, 2016

There is much discussion online and also in small, private groups, about why the price of technology companies – public and private – are falling. It pains me to see the typical (and predictable) responses on Twitter, “VCs want prices to drop!” ” “Sure, prices are dropping.

Startup 150

Startup Company Companies Venture Capital 150

Both Sides of the Table

OCTOBER 18, 2015

“Trade in an asset at a price that strongly deviates from an asset’s intrinsic value” The arguments against that, “This time the startups have real revenues!” “A price that strongly deviates from an assets intrinsic value” is pretty clear. ” How elegantly stated. ” ring hollow.

Venture Capital 150

Venture Capital Pricing Platform Marketing 150